BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QL2106 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QL2106\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07511647-1920@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:QL2106: Phase 3 readout est. (NCT07511647)
DESCRIPTION:QL2106\, phase 3\, Psoriasis.\nStudy: A Phase 3 Clinical Study 
 of QL2106 Injection\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ql2106#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07511647
URL:https://assetmemo.bio/drug/ql2106#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
